Clinical Trial Update: Cyclophosphamide, TAPA-Pulsed Dendritic Cell Therapy and Imiquimod in Progressive and/or Refractory Solid Malignancies [Phase 1, Phase 2]

View source ↗

Summary

A terminated Phase 1/2 trial evaluating cyclophosphamide, TAPA-pulsed dendritic cell therapy, and imiquimod in progressive or refractory solid malignancies.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer
• Progressive Solid Malignancies
• Solid Malignancies

Drugs mentioned

• CYCLOPHOSPHAMIDE (Cyclophosphamide)
• Imiquimod (imiquimod)
• TAPA-Pulsed Dendritic Cell Therapy (TAPA-pulsed dendritic cell therapy)

Snippet

Sponsor: Kiromic BioPharma Inc. | Conditions: Progressive Solid Malignancies, Refractory Solid Malignancies | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2020-04-24